Sabra Health Care REIT Stock Price and Value Analysis

Should you buy Sabra Health Care REIT stock? (NasdaqGS:SBRA). Let's see how it does in our automated value investing analysis system.

  • This company has a large dividend yield!
  • This company is solid.
  • This company has wild ups and downs.
  • This company is making money at a modest rate.
  • This stock looks fairly priced.

Inside the SBRA Numbers

SBRA Price
(Sabra Health Care REIT stock price per share)
[?] SBRA Fair Price
(based on intrinsic value)
[?] SBRA Safety Price (based on a variable margin of safety) $8.24
[?] PE Ratio versus Sector 179% higher than other Real Estate stocks
[?] PE Ratio versus Industry 21% higher than other Unknown stocks
[?] Cash Yield -5.15%
[?] Free Cash Flow Jitter 50%
[?] Dividend Yield 9%
Shares Shorted 8,447,826

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 8,447,826 shares shorted. With 228,088,690 shares available for purchase and an average trading volume over the past 10 trading days of 2,177,690, it would take at least 3.879 days for all of the short holders to cover their shorts.

Is Sabra Health Care REIT Stock on Sale?

We believe that Sabra Health Care REIT may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Sabra Health Care REIT looks like a price in the fair value range. Based on our analysis—if the company keeps making money the way it has been—you could be looking at a good stock. See Before You Buy for your next steps.

Should You Buy SBRA Stock?

Does Sabra Health Care REIT have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.